A61K31/04

Inorganic nitrite to improve cardiopulmonary hemodynamics

Disclosed herein are methods for treating acute or chronic heart failure using inorganic nitrite, such as sodium nitrite. The method includes administering to a subject in need of treatment a therapeutically effective amount of inorganic nitrite. The nitrite may be administered by inhalation and may be nebulized. The nitrite may be administered at an emitted dose or in an escalated titrated dose. The nitrite may be a liquid formulation or a dry powder formulation.

Inorganic nitrite to improve cardiopulmonary hemodynamics

Disclosed herein are methods for treating acute or chronic heart failure using inorganic nitrite, such as sodium nitrite. The method includes administering to a subject in need of treatment a therapeutically effective amount of inorganic nitrite. The nitrite may be administered by inhalation and may be nebulized. The nitrite may be administered at an emitted dose or in an escalated titrated dose. The nitrite may be a liquid formulation or a dry powder formulation.

NON-THERAPEUTIC METHODS FOR ALLEVIATING OR REDUCING STRESS SYMPTOMS OF RUMINANTS

Methods are disclosed for the reduction of stress in ruminants in need thereof by administering propanediol mononitrate or chloroform or a composition which includes propanediol mononitrate or chloroform to a ruminant prior to experiencing stress, while experiencing stress and/or after having experienced stress.

NON-THERAPEUTIC METHODS FOR ALLEVIATING OR REDUCING STRESS SYMPTOMS OF RUMINANTS

Methods are disclosed for the reduction of stress in ruminants in need thereof by administering propanediol mononitrate or chloroform or a composition which includes propanediol mononitrate or chloroform to a ruminant prior to experiencing stress, while experiencing stress and/or after having experienced stress.

Methods of treating HIV-associated neurological disorders (HAND)

In the present disclosure, doxycycline-inducible astrocyte-specific HIV Tat transgenic mice (iTat), a surrogate HAND model, were treated with PNU-125096, a positive allosteric modulator of α7 nicotinic acetylcholine receptor (α7 nAChR) and effects on Tat-induced behavioral impairments and neuropathologies were observed. This disclosure shows that PNU-125096 treatment significantly improved locomotor, learning and memory deficits of iTat mice while inhibited glial activation and increased PSD-95 expression in the cortex and hippocampus of iTat mice. α7 nAChR knockout eliminated the protective effects of PNU-125096 on iTat mice. In addition, inhibition of p38 phosphorylation by SB239063, a p38 MAPK-specific inhibitor, exacerbated Tat neurotoxicity in iTat mice. These findings demonstrated for the first time that α7 nAChR activation led to protection against HAND and suggest that α7 nAChR and PNU-125096 hold significant promise for development of therapeutics for HAND.

SOS1 ALLOSTERIC SITE TARGETING

Disclosed herein are small molecule SOS1 allosteric site inhibitors, pharmaceutical compositions, and methods of use thereof.

SOS1 ALLOSTERIC SITE TARGETING

Disclosed herein are small molecule SOS1 allosteric site inhibitors, pharmaceutical compositions, and methods of use thereof.

Composition for treating wounds, dermatitis, inflammation, and irritation
11759418 · 2023-09-19 · ·

A composition comprising effective amounts of benzalkonium chloride, allantoin, and nitrofurazone in a water soluble base for treating wounds and skin conditions, such as dermatitis is described. Methods of treating skin conditions and accelerating wound healing are also described.

Composition for treating wounds, dermatitis, inflammation, and irritation
11759418 · 2023-09-19 · ·

A composition comprising effective amounts of benzalkonium chloride, allantoin, and nitrofurazone in a water soluble base for treating wounds and skin conditions, such as dermatitis is described. Methods of treating skin conditions and accelerating wound healing are also described.

Compositions for topical treatment of microbial infections
11786454 · 2023-10-17 · ·

The present invention provides compositions and methods for topical treatment of infections. The compositions comprise glycerol monolaurate or a derivative thereof, and are administered topically, for example, to treat viral, fungal or bacterial infections.